NSE / BSEHealthcare
β‚Ή830.50-14.30-1.69%
P/E32.6Mkt Capβ‚Ή5.94 K CrEV/EBITDA31.4

Supriya Lifescience Limited

P/E32.6Mkt Capβ‚Ή5.94 K CrEV/EBITDA31.4
Company Profile

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antiΒ–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 23.62% over 1Y
Monthly Returns

Historically, Aug has averaged the highest return (+9.9%); Jan the lowest (-5.7%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-9.8%Negative MonthJan 2026: -9.83%-3.4%Negative MonthFeb 2026: -3.41%-13.5%Negative MonthMar 2026: -13.51%+22.9%Positive MonthApr 2026: +22.90%+11.5%Positive MonthMay 2026: +11.50%+31.4%Positive MonthJun 2026: +31.37%-18.4%*Negative MonthJul 2026: -18.36%β€”β€”β€”β€”β€”
2025-2.6%Negative MonthJan 2025: -2.57%-17.0%Negative MonthFeb 2025: -16.97%+22.6%Positive MonthMar 2025: +22.56%-12.1%Negative MonthApr 2025: -12.10%+12.2%Positive MonthMay 2025: +12.21%-2.2%Negative MonthJun 2025: -2.25%-6.3%Negative MonthJul 2025: -6.35%-1.5%Neutral MonthAug 2025: -1.50%+11.7%Positive MonthSep 2025: +11.67%+6.5%Positive MonthOct 2025: +6.45%-3.5%Negative MonthNov 2025: -3.47%+0.2%Neutral MonthDec 2025: +0.19%
2024-3.0%Negative MonthJan 2024: -2.97%+12.6%Positive MonthFeb 2024: +12.58%-3.4%Negative MonthMar 2024: -3.45%+19.8%Positive MonthApr 2024: +19.80%-7.8%Negative MonthMay 2024: -7.79%+5.4%Positive MonthJun 2024: +5.38%+3.3%Positive MonthJul 2024: +3.28%+37.0%Positive MonthAug 2024: +36.96%+3.1%Positive MonthSep 2024: +3.10%+10.8%Positive MonthOct 2024: +10.77%+24.5%Positive MonthNov 2024: +24.46%-4.7%Negative MonthDec 2024: -4.71%
2023-8.6%Negative MonthJan 2023: -8.60%-7.9%Negative MonthFeb 2023: -7.88%-3.8%Negative MonthMar 2023: -3.76%+13.7%Positive MonthApr 2023: +13.71%+14.3%Positive MonthMay 2023: +14.27%+0.0%Neutral MonthJun 2023: +0.02%+2.7%Positive MonthJul 2023: +2.70%+10.0%Positive MonthAug 2023: +10.04%+0.2%Neutral MonthSep 2023: +0.21%-10.9%Negative MonthOct 2023: -10.88%+16.4%Positive MonthNov 2023: +16.43%+8.0%Positive MonthDec 2023: +8.00%
2022-4.5%Negative MonthJan 2022: -4.54%-8.9%Negative MonthFeb 2022: -8.93%+17.3%Positive MonthMar 2022: +17.26%-15.0%Negative MonthApr 2022: -14.98%-14.8%Negative MonthMay 2022: -14.78%-0.0%Neutral MonthJun 2022: -0.01%+5.6%Positive MonthJul 2022: +5.63%-6.0%Negative MonthAug 2022: -5.95%-15.4%Negative MonthSep 2022: -15.44%-4.2%Negative MonthOct 2022: -4.18%-14.9%Negative MonthNov 2022: -14.91%-3.8%Negative MonthDec 2022: -3.76%
2021β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”
AvgΒ±SD-5.7%Β±3.0%-4.9%Β±9.8%+3.8%Β±13.7%+5.9%Β±16.1%+3.1%Β±12.0%+6.9%Β±12.5%-2.6%Β±8.9%+9.9%Β±16.7%-0.1%Β±9.8%+0.5%Β±8.5%+5.6%Β±15.6%-0.1%Β±5.0%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.107x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή696.00 Crβ–² 22.1%
EBITDA Growthβ€”
Net Profitβ‚Ή188.00 Crβ–² 58.0%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 104.8%
Revenue CAGR 5Y12.8%
EBITDA CAGR 5Y11.4%
Net Profit CAGR 5Y10.3%
NP Growth 1Y58.0%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή696.00 Crβ€”β‚Ή188.00 Crβ€”β€”18.9%22.1%58.0%
Mar 2024β‚Ή570.00 Crβ€”β‚Ή119.00 Crβ€”β€”14.6%23.6%32.2%
Mar 2023β‚Ή461.00 Crβ€”β‚Ή90.00 Crβ€”β€”12.9%-13.0%-40.8%
Mar 2022β‚Ή530.00 Crβ€”β‚Ή152.00 Crβ€”β€”24.7%35.5%22.6%
Mar 2021β‚Ή391.00 Crβ€”β‚Ή124.00 Crβ€”β€”46.1%25.3%69.9%
Mar 2020β‚Ή312.00 Crβ€”β‚Ή73.00 Crβ€”β€”49.0%12.2%87.2%
Mar 2019β‚Ή278.00 Crβ€”β‚Ή39.00 Crβ€”β€”41.5%30.5%333.3%
Mar 2018β‚Ή213.00 Crβ€”β‚Ή9.00 Crβ€”β€”16.4%15.8%50.0%
Mar 2017β‚Ή184.00 Crβ€”β‚Ή6.00 Crβ€”β€”13.0%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales184213278312391530461570696715
Total Expenses166191213213218316332394436457
EBIT / Operating Profit17226598173214129176261258
OPM %9%10%23%32%44%40%28%31%37%36%
Other Income79811589111010
Finance Costs1211107443522
Depreciation & Amortisation555671012162024
Profit Before Tax8145796167207123166248242
Tax %30%40%31%24%26%27%27%28%24%-
Net Profit / PAT69397312415290119188182
EPS (β‚Ή)3.875.9626.9350.1116.8918.8611.1714.8023.3522.66
Dividend Payout %0%0%0%20%3%3%5%5%4%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Supriya Lifescience Limitedthis co.β‚Ή5.94 K Crβ‚Ή696.00 Cr32.605.5131.3522.1%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Supriya Lifescience Limited and the metrics that matter.

Browse the full Equiscale Academy